Physician profile
Sandeep Mukherjee
NPI 1760432066
$145,166.50
in general payments reported to CMS, 2019-2025
16 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,168 · 2021: $8,226 · 2022: $7,932 · 2023: $20K · 2024: $35K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Travel and Lodging: $7,413 · Honoraria: $6,812 · Food and Beverage: $2,511 · Consulting Fee: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,389.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,160.00 |
| Travel and Lodging | $7,412.85 |
| Honoraria | $6,811.63 |
| Food and Beverage | $2,511.47 |
| Consulting Fee | $1,240.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $76,396.51 | 2019-2025 | Livdelzi, Epclusa |
| Ipsen Biopharmaceuticals, INC | $39,697.22 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $15,031.14 | 2020-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $12,814.18 | 2024-2025 | Rezdiffra |
| Boston Scientific Corporation | $724.70 | 2019 | |
| Illumina, INC. | $190.00 | 2023 | Oncology Testing |
| Abbvie INC. | $122.71 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $69.21 | 2019-2022 | |
| Genzyme Corporation | $27.86 | 2024 | |
| Abbott Laboratories | $27.81 | 2023 | Alinity M |
| Viiv Healthcare Company | $17.96 | 2023 | Cabenuva |
| Lilly USA, LLC | $16.91 | 2025 | Omvoh |
| Welch Allyn | $16.90 | 2021 | |
| Celgene Corporation | $13.39 | 2023 | Zeposia |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Mukherjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.